Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 6/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21485598 | 0.91 | NTRK1 (0.37) | NTRK1CNR2CNR1FFAR4KLK7 | |
| SCHEMBL21458273 | 0.91 | NTRK1 (0.37) | NTRK1CNR2CNR1FFAR4KLK7 | |
| SCHEMBL21481971 | 0.86 | CRHR1 (0.40) | CNR2CNR1CRHR1KLK7 | |
| SCHEMBL21481881 | 0.86 | CRHR1 (0.42) | CNR2CNR1CRHR1CRHR2SLC6A12 | |
| SCHEMBL21481869 | 0.86 | CRHR1 (0.42) | CNR2CNR1CRHR1CRHR2SLC6A12 | |
| SCHEMBL21481960 | 0.84 | MEN1 (0.41) | CNR2CNR1CRHR1FFAR4KLK7 | |
| SCHEMBL21506526 | 0.82 | DRD4 (0.41) | CNR2CNR1CRHR1DRD4SLC6A12 | |
| SCHEMBL21506649 | 0.82 | CRHR1 (0.37) | CNR2CNR1CRHR1DRD4 | |
| SCHEMBL21482146 | 0.81 | MCHR1 (0.45) | CNR2CNR1CRHR1KLK7CRHR2 | |
| SCHEMBL21482122 | 0.81 | PRKAA2 (0.43) | CNR2CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| WO-2019204523-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | NTRK1 1600/4885CNR2 3/4885CNR1 6/4885 |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | NTRK1 1600/4885CNR2 3/4885CNR1 6/4885 |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | NTRK1 1600/4885CNR2 3/4885CNR1 6/4885 |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | NTRK1 1600/4885CNR2 3/4885CNR1 6/4885 |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | NTRK1 1600/4885CNR2 3/4885CNR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.